deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04933695

A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment (CodeBreaK201)

A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201)

Sponsor: Amgen

Conditions Non-small Cell Lung Cancer
Interventions Sotorasib
Updated 21 times since 2021 Last updated: Oct 21, 2025 Started: Jan 28, 2022 Primary completion: May 27, 2025 Completion: May 27, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Non-small Cell Lung Cancer and is currently completed. Amgen leads this study, which shows 21 recorded versions since 2022 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2021 – ~Nov 2021 · 2 months · monthly snapshot~Nov 2021 – ~Jan 2022 · 2 months · monthly snapshot~Jan 2022 – ~Feb 2022 · 31 days · monthly snapshot~Feb 2022 – ~Mar 2022 · 28 days · monthly snapshot~Mar 2022 – ~Apr 2022 · 31 days · monthly snapshot~Apr 2022 – ~May 2022 · 30 days · monthly snapshot~May 2022 – ~Jun 2022 · 31 days · monthly snapshot~Jun 2022 – ~Jul 2022 · 30 days · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Mar 2023 · 3 months · monthly snapshot~Mar 2023 – ~May 2023 · 2 months · monthly snapshot~May 2023 – ~Nov 2023 · 6 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Dec 2024 · 3 months · monthly snapshot~Dec 2024 – ~Jun 2025 · 6 months · monthly snapshot~Jun 2025 – ~Jul 2025 · 30 days · monthly snapshot~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Nov 2025 · 2 months · monthly snapshot~Nov 2025 – present · 9 months · monthly snapshot

Change History

21 versions recorded

  1. Nov 2025 — Present [monthly]

    Completed PHASE2

  2. Sep 2025 — Nov 2025 [monthly]

    Completed PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Jun 2025 — Jul 2025 [monthly]

    Active Not Recruiting PHASE2

  5. Dec 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE2

▶ Show 16 earlier versions

  1. Sep 2024 — Dec 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  4. May 2023 — Nov 2023 [monthly]

    Active Not Recruiting PHASE2

  5. Mar 2023 — May 2023 [monthly]

    Active Not Recruiting PHASE2

  6. Dec 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

  7. Sep 2022 — Dec 2022 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  8. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  9. Jun 2022 — Jul 2022 [monthly]

    Recruiting PHASE2

  10. May 2022 — Jun 2022 [monthly]

    Recruiting PHASE2

  11. Apr 2022 — May 2022 [monthly]

    Recruiting PHASE2

  12. Mar 2022 — Apr 2022 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Feb 2022 — Mar 2022 [monthly]

    Not Yet Recruiting PHASE2

  14. Jan 2022 — Feb 2022 [monthly]

    Not Yet Recruiting PHASE2

  15. Nov 2021 — Jan 2022 [monthly]

    Not Yet Recruiting PHASE2

  16. Sep 2021 — Nov 2021 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Amgen
Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Amsterdam, Netherlands , Ankara, Turkey (Türkiye) , Avignon, France , Barcelona, Spain , Birmingham, United States , Brussels, Belgium , Charleston, United States , Cologne, Germany , Dallas, United States , Denton, United States and 49 more locations